Posted in | News | Nanobusiness

Neuftec Comments on Fundamental Inaccuracy In Oxonica's AGM Statement

Neuftec Limited, the proprietor of the original nano-particulate cerium oxide fuel catalyst technology, which recently issued a claim against Oxonica Energy Limited, a wholly owned subsidiary of Oxonica PLC, for infringement of its European Patent in the High Court of Justice, has commented on a fundamental inaccuracy in Oxonica's AGM Statement issued by Dr Matthews (CEO) on 19 June 2008.

Dr Kevin Matthews stated in the recent Regulatory Announcement that: "In 2007 Neuftec acknowledged that Envirox as supplied by Nyacol, Oxonica's strategic partner, does not fall within the claims of their granted patent, EP(UK) 1299 508."

In May 2007, Oxonica provided Neuftec with a confidential statement containing what it claimed to be the chemical composition of Envirox sold to Petrol Ofisi. Based on that information alone, Neuftec confirmed in June 2007 that the second source product supplied to Petrol Ofisi did not come within the scope of claims of Neuftec's patent. Neuftec has never acknowledged that Envirox products sold to customers other than Petrol Ofisi did not infringe Neuftec's European patent.

Neuftec has obtained samples of Oxonica's Envirox formulation produced by Nyacol and conducted a preliminary analysis of the formulation. The results of this analysis confirm that the Nyacol Envirox formulation does not match the compostion statement issued to Neuftec by Oxonica. Neuftec Limited thus reserves its position regarding its rights to claim infringement in respect of all other formulations of Envirox supplied to other parties.

As reported earlier this month, the latest alleged infringement occurred when Oxonica shipped Envirox formulations to Italy for use in Italian Government laboratory emission testing. Neuftec is continuing it's investigations with customers, distributors & agents of Oxonica to determine the extent of the alleged infringement. Neuftec issued proceedings to seek an injunction against Oxonica as well as damages in relation to product already sold and delivery up or destruction of all articles that would infringe Neuftec's European patent.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Oxonica Inc.. (2019, March 19). Neuftec Comments on Fundamental Inaccuracy In Oxonica's AGM Statement. AZoNano. Retrieved on November 21, 2024 from https://www.azonano.com/news.aspx?newsID=12473.

  • MLA

    Oxonica Inc.. "Neuftec Comments on Fundamental Inaccuracy In Oxonica's AGM Statement". AZoNano. 21 November 2024. <https://www.azonano.com/news.aspx?newsID=12473>.

  • Chicago

    Oxonica Inc.. "Neuftec Comments on Fundamental Inaccuracy In Oxonica's AGM Statement". AZoNano. https://www.azonano.com/news.aspx?newsID=12473. (accessed November 21, 2024).

  • Harvard

    Oxonica Inc.. 2019. Neuftec Comments on Fundamental Inaccuracy In Oxonica's AGM Statement. AZoNano, viewed 21 November 2024, https://www.azonano.com/news.aspx?newsID=12473.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.